Abstract
Background Mycoplasma pneumoniae strains with resistance to macrolides have been spreading worldwide. Here, we aimed to clarify which antimicrobial agent is a better treatment for patients with M. pneumoniae pneumonia in a setting with large epidemics of macrolide resistance. Methods Adult patients hospitalized with laboratory-confirmed M. pneumoniae pneumonia from 2010 to 2013 were identified from the Japanese Diagnosis Procedure Combination national database. Drug switching, length of stay (LOS), 30-day mortality, and total costs for patients who underwent macrolide, quinolone, and tetracycline therapy were compared using propensity score analyses. Results Eligible patients (N = 1650) from 602 hospitals were divided into the macrolide group (n = 508), quinolone group (n = 569), or tetracycline group (n = 573). We found that 52.8%, 21.8%, and 38.6% of patients in the macrolide, quinolone, and tetracycline groups, respectively, had to switch drugs (P
Author supplied keywords
Cite
CITATION STYLE
Tashiro, M., Fushimi, K., Kawano, K., Takazono, T., Saijo, T., Yamamoto, K., … Izumikawa, K. (2017). Comparison of Efficacy of Antimicrobial Agents among Hospitalized Patients with Mycoplasma pneumoniae Pneumonia in Japan during Large Epidemics of Macrolide-Resistant M. pneumoniae Infections: A Nationwide Observational Study. Clinical Infectious Diseases, 65(11), 1837–1842. https://doi.org/10.1093/cid/cix695
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.